• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

PIK3CA基因改变在非肌层浸润性膀胱癌中对EZH2信号传导的相反作用。

Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.

作者信息

Segovia Cristina, Martínez-Fernández Mónica, Dueñas Marta, Rubio Carolina, López-Calderón Fernando F, Costa Clotilde, Saiz-Ladera Cristina, Fernández-Grajera María, Duarte José, Muñoz Huberto García, de la Rosa Federico, Villacampa Felipe, Castellano Daniel, Paramio Jesús M

机构信息

Unidad de Oncología Molecular, CIEMAT (ed70A), Madrid, Spain.

Grupo de Oncología celular y Molecular, Hospital Universitario 12 de Octubre, Madrid, Spain.

出版信息

Oncotarget. 2017 Feb 7;8(6):10531-10542. doi: 10.18632/oncotarget.14453.

DOI:10.18632/oncotarget.14453
PMID:28060766
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5354678/
Abstract

The high rates of tumor recurrence and progression represent a major clinical problem in non-muscle invasive bladder cancer. Previous data showed that EZH2-dependent signaling mediates these processes, whereas the frequent alterations of PIK3CA gene (copy gains and mutations) are predictive of reduced recurrence. Here we show, using clinical samples and bladder cancer cell lines, a functional interaction between EZH2- and PIK3CA-dependent signaling pathways. PIK3CA alterations mediated, on the one hand, the increased expression of two miRNAs, miR-101 and miR-138, which posttranscriptionally downregulate EZH2 expression. On the other hand, PIK3CA alterations facilitate the activation of Akt which phosphorylates EZH2 on Ser21, precluding the trimethylation of histone H3 in K27. Remarkably the increased expression of miR101 or miR138 and the expression of Ser21-phosphorylated EZH2 are good prognostic factors regarding non-muscle invasive bladder cancer recurrence and progression. Collectively, this study provides molecular evidences indicating that the gene expression rewiring occurring in primary bladder tumors, associated with increased EZH2 expression and activity and mediating the increased recurrence and progression risk, are prevented by PIK3CA-dependent signaling. This molecular process may have deep implications in the management of bladder cancer patients and in the design of novel molecularly targeted therapeutic approaches.

摘要

肿瘤复发和进展的高发生率是非肌肉浸润性膀胱癌的一个主要临床问题。先前的数据表明,EZH2依赖性信号传导介导了这些过程,而PIK3CA基因的频繁改变(拷贝数增加和突变)可预测复发率降低。在此,我们使用临床样本和膀胱癌细胞系表明,EZH2依赖性和PIK3CA依赖性信号通路之间存在功能相互作用。一方面,PIK3CA改变介导了两种miRNA,即miR-101和miR-138的表达增加,它们在转录后下调EZH2表达。另一方面,PIK3CA改变促进了Akt的激活,Akt使EZH2的Ser21位点磷酸化,从而阻止组蛋白H3在K27位点的三甲基化。值得注意的是,miR101或miR138的表达增加以及Ser21磷酸化的EZH2的表达是非肌肉浸润性膀胱癌复发和进展的良好预后因素。总的来说,这项研究提供了分子证据,表明原发性膀胱肿瘤中发生的基因表达重排,与EZH2表达和活性增加相关并介导复发和进展风险增加,可被PIK3CA依赖性信号传导阻止。这一分子过程可能对膀胱癌患者的管理以及新型分子靶向治疗方法的设计具有深远意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa87/5354678/dc3ef6172104/oncotarget-08-10531-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa87/5354678/079eee2b79ae/oncotarget-08-10531-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa87/5354678/ce1258839302/oncotarget-08-10531-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa87/5354678/ed21b3eb5da8/oncotarget-08-10531-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa87/5354678/dc3ef6172104/oncotarget-08-10531-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa87/5354678/079eee2b79ae/oncotarget-08-10531-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa87/5354678/ce1258839302/oncotarget-08-10531-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa87/5354678/ed21b3eb5da8/oncotarget-08-10531-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa87/5354678/dc3ef6172104/oncotarget-08-10531-g004.jpg

相似文献

1
Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.PIK3CA基因改变在非肌层浸润性膀胱癌中对EZH2信号传导的相反作用。
Oncotarget. 2017 Feb 7;8(6):10531-10542. doi: 10.18632/oncotarget.14453.
2
PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.PIK3CA基因改变在膀胱癌中很常见,且与非肌层浸润性肿瘤复发率降低相关。
Mol Carcinog. 2015 Jul;54(7):566-76. doi: 10.1002/mc.22125. Epub 2013 Dec 18.
3
Liquid Biopsy Analysis of FGFR3 and PIK3CA Hotspot Mutations for Disease Surveillance in Bladder Cancer.膀胱癌疾病监测中的液体活检分析 FGFR3 和 PIK3CA 热点突变
Eur Urol. 2017 Jun;71(6):961-969. doi: 10.1016/j.eururo.2016.12.016. Epub 2017 Jan 6.
4
A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.一种多梳蛋白-mir200环调控膀胱癌的临床结局。
Oncotarget. 2015 Dec 8;6(39):42258-75. doi: 10.18632/oncotarget.5546.
5
Honokiol inhibits bladder tumor growth by suppressing EZH2/miR-143 axis.厚朴酚通过抑制EZH2/miR-143轴来抑制膀胱肿瘤生长。
Oncotarget. 2015 Nov 10;6(35):37335-48. doi: 10.18632/oncotarget.6135.
6
EZH2 in Bladder Cancer, a Promising Therapeutic Target.EZH2在膀胱癌中:一个有前景的治疗靶点
Int J Mol Sci. 2015 Nov 13;16(11):27107-32. doi: 10.3390/ijms161126000.
7
The CUL4B-miR-372/373-PIK3CA-AKT axis regulates metastasis in bladder cancer.CUL4B- miR-372/373-PIK3CA-AKT 轴调控膀胱癌转移。
Oncogene. 2020 Apr;39(17):3588-3603. doi: 10.1038/s41388-020-1236-1. Epub 2020 Mar 3.
8
miR-144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling.miR-144 的下调通过靶向 EZH2 并调节 Wnt 信号通路增加膀胱癌细胞的增殖。
FEBS J. 2013 Sep;280(18):4531-8. doi: 10.1111/febs.12417. Epub 2013 Jul 25.
9
Overexpression of CircRNA BCRC4 regulates cell apoptosis and MicroRNA-101/EZH2 signaling in bladder cancer.环状RNA BCRC4的过表达调控膀胱癌中的细胞凋亡和微小RNA-101/增强子结合蛋白2信号通路。
J Huazhong Univ Sci Technolog Med Sci. 2017 Dec;37(6):886-890. doi: 10.1007/s11596-017-1822-9. Epub 2017 Dec 21.
10
Assessment of prognostic implication of a panel of oncogenes in bladder cancer and identification of a 3-gene signature associated with recurrence and progression risk in non-muscle-invasive bladder cancer.评估一组癌基因在膀胱癌中的预后意义,并鉴定与非肌肉浸润性膀胱癌复发和进展风险相关的 3 个基因特征。
Sci Rep. 2020 Oct 6;10(1):16641. doi: 10.1038/s41598-020-73642-8.

引用本文的文献

1
Predictive Molecular Biomarkers of Bladder Cancer Identified by Next-Generation Sequencing-Preliminary Data.通过下一代测序确定的膀胱癌预测性分子生物标志物——初步数据
J Clin Med. 2024 Dec 17;13(24):7701. doi: 10.3390/jcm13247701.
2
Epigenomic and Metabolomic Integration Reveals Dynamic Metabolic Regulation in Bladder Cancer.表观基因组学与代谢组学整合揭示膀胱癌中的动态代谢调控
Cancers (Basel). 2021 May 31;13(11):2719. doi: 10.3390/cancers13112719.
3
Advances in urinary biomarker discovery in urological research.在泌尿学研究中尿液生物标志物的发现进展。

本文引用的文献

1
EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.EAU 指南:非肌层浸润性膀胱尿路上皮癌:2016 年更新版。
Eur Urol. 2017 Mar;71(3):447-461. doi: 10.1016/j.eururo.2016.05.041. Epub 2016 Jun 17.
2
Enrichr: a comprehensive gene set enrichment analysis web server 2016 update.Enrichr:一个全面的基因集富集分析网络服务器2016年更新版。
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7. doi: 10.1093/nar/gkw377. Epub 2016 May 3.
3
Targeting EZH2 in cancer.在癌症中靶向EZH2
Investig Clin Urol. 2020 Feb;61(Suppl 1):S8-S22. doi: 10.4111/icu.2020.61.S1.S8. Epub 2019 Dec 31.
4
Epigenetics of Bladder Cancer: Where Biomarkers and Therapeutic Targets Meet.膀胱癌的表观遗传学:生物标志物与治疗靶点的交汇之处
Front Genet. 2019 Nov 18;10:1125. doi: 10.3389/fgene.2019.01125. eCollection 2019.
5
Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status.非肌肉浸润性膀胱癌的基因表达分析揭示了可变剪接和 Tp53 状态的作用。
Sci Rep. 2019 Jul 17;9(1):10362. doi: 10.1038/s41598-019-46652-4.
6
Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression.抑制 G9a/DNMT 网络可触发免疫介导的膀胱癌消退。
Nat Med. 2019 Jul;25(7):1073-1081. doi: 10.1038/s41591-019-0499-y. Epub 2019 Jul 3.
7
Cell-free DNA in blood and urine as a diagnostic tool for bladder cancer: a meta-analysis.血液和尿液中的游离DNA作为膀胱癌的诊断工具:一项荟萃分析。
Am J Transl Res. 2018 Jul 15;10(7):1935-1948. eCollection 2018.
8
MiR-101 inhibits ovarian carcinogenesis by repressing the expression of brain-derived neurotrophic factor.微小RNA-101通过抑制脑源性神经营养因子的表达来抑制卵巢癌发生。
FEBS Open Bio. 2017 Aug 29;7(9):1258-1266. doi: 10.1002/2211-5463.12257. eCollection 2017 Sep.
9
Accuracy of the urine UCA1 for diagnosis of bladder cancer: a meta-analysis.尿UCA1用于膀胱癌诊断的准确性:一项荟萃分析。
Oncotarget. 2017 May 23;8(21):35222-35233. doi: 10.18632/oncotarget.16473.
Nat Med. 2016 Feb;22(2):128-34. doi: 10.1038/nm.4036.
4
RNA Detection in Urine: From RNA Extraction to Good Normalizer Molecules.尿液中的RNA检测:从RNA提取到优质标准化分子
J Mol Diagn. 2016 Jan;18(1):15-22. doi: 10.1016/j.jmoldx.2015.07.008. Epub 2015 Nov 14.
5
EZH2 in Bladder Cancer, a Promising Therapeutic Target.EZH2在膀胱癌中:一个有前景的治疗靶点
Int J Mol Sci. 2015 Nov 13;16(11):27107-32. doi: 10.3390/ijms161126000.
6
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma.磷酸化介导的EZH2失活促进多发性骨髓瘤的耐药性。
J Clin Invest. 2015 Oct 26;125(12):4375-90. doi: 10.1172/JCI80325.
7
A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.一种多梳蛋白-mir200环调控膀胱癌的临床结局。
Oncotarget. 2015 Dec 8;6(39):42258-75. doi: 10.18632/oncotarget.5546.
8
Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer.膀胱癌中多梳相关长链非编码RNA HOTAIR和ANRIL的分析
Clin Epigenetics. 2015 Oct 8;7:109. doi: 10.1186/s13148-015-0141-x. eCollection 2015.
9
The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.UBC - 40膀胱癌细胞系索引:用于功能研究的基因组资源。
BMC Genomics. 2015 May 22;16(1):403. doi: 10.1186/s12864-015-1450-3.
10
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity.膀胱癌的分子生物学:发病机制和临床多样性的新见解。
Nat Rev Cancer. 2015 Jan;15(1):25-41. doi: 10.1038/nrc3817.